NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

中國的Sitagliptin市場分析 (2021年∼2025年)

Investigation Report on China's Sitagliptin Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1009413
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的Sitagliptin市場分析 (2021年∼2025年) Investigation Report on China's Sitagliptin Market 2021-2025
出版日期: 2021年06月04日內容資訊: 英文 50 Pages
簡介

Sitagliptin是世界第一個口服Dipeptidyl Peptidase-4 (DPP-4) 抑制劑,2009年9月,核可進入中國市場。2020年時,Merck Sharp & Dohme Ltd是中國市場是唯一的廠商。中國國內的Sitagliptin的銷售額,從2017年的1億1698萬人民幣,達2018年2億3337萬人民幣,2020年3億8969萬人民幣。由於2022年專利屆滿,預計與進入市場其他企業競爭激烈、價格下降,市場規模進一步擴大。

本報告提供中國的Sitagliptin的市場相關分析,產品的概要和授權情形,整體市場規模趨勢預測 (2016年∼2020年/2021年∼2025年),各地區的詳細趨勢,市場價格趨勢預測,主要企業的簡介與市場佔有率,主要的推動及阻礙市場要素等彙整資訊,為您概述為以下內容。

目錄

第1章 Sitagliptin的相關概念

  • Sitagliptin的適應症
  • 中國國內的Sitagliptin的開發趨勢
  • 中國政府的Sitagliptin的核準情況
  • COVID-19對中國的Sitagliptin銷售的影響

第2章 中國國內的Sitagliptin銷售趨勢 (2016年∼2020年)

  • Sitagliptin的銷售額
    • 總銷售額
    • 各地區的銷售額
  • Sitagliptin的銷售量
    • 總銷售量
    • 各地區的銷售量
  • 中國國內的Sitagliptin銷售趨勢:各劑型 (2016年∼2020年)
    • 片劑
    • 其他劑型

第3章 中國的Sitagliptin主要製造商分析 (2016年∼2020年)

  • 主要Sitagliptin製造商市場佔有率分析
    • 市場佔有率:銷售額為基礎
    • 市場佔有率:銷售量為基礎
  • Merck Sharp & Dohme Ltd
    • 企業簡介
    • 中國的Sitagliptin銷售趨勢

第4章 中國的Sitagliptin的價格趨勢:各主要製造商 (2020年∼2021年)

  • Merck Sharp & Dohme Ltd (JANUVIA)
  • 其他企業分析

第5章 中國的Sitagliptin市場未來展望 (2021年∼2025年)

  • 左右中國的Sitagliptin市場趨勢的要素
    • COVID-19對中國的Sitagliptin市場的影響
    • 市場促進因素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2106513

Sitagliptin is the world's first listed oral dipeptidyl peptidase-4 (DPP-4) inhibitor, developed by Merck Sharp & Dohme Ltd (JANUVIA). It was approved by the U.S. FDA in October 2006 to be used as a single drug or combination with metformin and thiazolidinedione drugs to improve blood sugar control in type II diabetes. In April 2007, a combination of Sitagliptin and metformin was approved in the United States; in September 2009, the CFDA approved Sitagliptin to enter the Chinese market; in July 2012, the CFDA approved the registration of its combination in China. By 2020, Merck Sharp & Dohme Ltd is the only manufacturers in the Sitagliptin market in China.

According to CRI's market research, Sitagliptin's sales in the Chinese market have increased year by year. Sitagliptin was included in the medical insurance reimbursement catalog in 2017, so the sales value of China's Sitagliptin growth in 2018 was the most obvious, rising from CNY116.98 million in 2017 to CNY233.37 million in 2018, with an annual growth rate of 99.50%. In 2020, due to the impact of the COVID-19 epidemic, the growth rate of Sitagliptin sales fell, but the sale value of Sitagliptin reached CNY389.69 million. The CAGR of Sitagliptin's sales value in the Chinese market from 2016 to 2020 is 47.44%.

CRI expects that its sales will continue to grow from 2021 to 2025 as the effective alleviation of the COVID-19 epidemic. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. successfully won the first domestic imitation of Sitagliptin after the approval in 2020, and became the fourth domestically-made DPP-4 inhibitor drug. The patent of Sitagliptin will expire in 2022. In the future, its manufacturers will gradually increase, the market will continue to expand, and prices will have a downward trend, which will lead to an increase in Sitagliptin sales and sales volume. Compared with traditional hypoglycemic drugs, sitagliptin does not increase the risk of hypoglycemia and affect weight Neutrality, good cardiovascular safety and other advantages. Based on these advantages, Sitagliptin ranks the first in the DPP-4 inhibitor market. In addition, the huge patient population. The huge patient population will enable the Sitagliptin market to continue to expand. Therefore, Sitagliptin sales will continue to grow from 2021 to 2025 as the market expands.

Topics Covered:

  • The impact of COVID-19 on China's Sitagliptin market
  • Sales value of China's Sitagliptin 2016-2020
  • Competitive landscape of China's Sitagliptin market
  • Prices of Sitagliptin in China
  • Prices of Sitagliptin in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Sitagliptin market
  • Prospect of China's Sitagliptin market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Sitagliptin

  • 1.1 Indications for Sitagliptin
  • 1.2 Development of Sitagliptin in China
  • 1.3 Governmental Approval of Sitagliptin in China
  • 1.4 The Impact of COVID-19 on Sitagliptin sales in China

2 Sales of Sitagliptin in China, 2016-2020

  • 2.1 Sales Value of Sitagliptin
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Sitagliptin
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Sitagliptin by Dosage Form in China, 2016-2020
    • 2.3.1 Tablets
    • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Sitagliptin Manufacturers in China, 2016-2020

  • 3.1 Analysis of Market Share of Major Sitagliptin Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Merck Sharp & Dohme Ltd
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of JANUVIA (Merck Sharp & Dohme Ltd's Sitagliptin) in China

4 Prices of Sitagliptin for Different Manufacturers in China, 2020-2021

  • 4.1 Merck Sharp & Dohme Ltd (JANUVIA)
  • 4.2 Analysis of Other Enterprises

5 Prospect of Chinese Sitagliptin drug Market, 2021-2025

  • 5.1 Influential Factors of Chinese Sitagliptin Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Sitagliptin Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Sitagliptin Tablets Registration in China
  • Chart Sales Value of Sitagliptin Tablets over the World
  • Chart Sales Value of Sitagliptin Tablets in China, 2016-2020
  • Chart Sales Value of Sitagliptin Tablets in China by Region, 2016-2020
  • Chart Sales Volume of Sitagliptin Tablets in China, 2016-2020
  • Chart Sales Volume of Sitagliptin Tablets in China by Region, 2016-2020
  • Chart Market Share by Sales Value of Top Sitagliptin Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of JANUVIA in China, 2016-2020
  • Chart Referential Prices of JANUVIA in China, 2020-2021
  • Chart Forecast on Sales Value of Sitagliptin in China, 2021-2025
  • Chart Forecast on Sales Volume of Sitagliptin in China, 2021-2025